Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00659659 | A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma | PHASE1 | COMPLETED | 27 | — | — | Jan 1, 2008 | Mar 1, 2011 | Oct 10, 2012 | 11 | United States, Canada |
| NCT00512486 | A Sequential Dose-Escalation Study in Subjects With Mild Asthma | PHASE1 | COMPLETED | 42 | — | — | Nov 1, 2006 | Oct 1, 2008 | Nov 27, 2008 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MEDI-563 |
| 2 | EXPERIMENTAL | MEDI-563 |
| 4 | PLACEBO_COMPARATOR | Placebo |
| 5 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MEDI-563 | DRUG | 1.0 mg/kg IV: MEDI-563 |
| Placebo Comp. | OTHER | Placebo SC |
| Placebo | OTHER | Placebo as a single IV infusion (Certain number of subjects) |
Inclusion Criteria: * Male or female adults, 18 through 65 years of age at time of randomization; * Written informed consent obtained from the subject prior to beginning study procedures or receipt of any study medication; * Previously documented diagnosis of asthma of ≥ 1 year duration, based on e...